Nestle near deal for Pfizer's baby formula unit - WSJ

Wed Apr 18, 2012 6:39am IST

Related Topics

Stocks

   

REUTERS - Pfizer Inc (PFE.N) is near a deal to sell its baby formula business to Swiss food giant Nestle SA (NESN.VX) for at least $9 billion, the Wall Street Journal reported on Tuesday.

Citing people familiar with the matter, the Journal said Nestle appears to have outstripped Danone and Mead Johnson Nutrition Co, who had teamed up for a bid, and that a deal could be announced as soon as next week.

Nestle, the world's biggest packaged food company, was already seen as a favored bidder due largely to its deep pockets.

Bloomberg reported that Danone and Nestle both submitted final offers of about $10 billion for the business, citing people with knowledge of the matter.

According to that report, Danone has told outsiders that it is unlikley to win the unit, but that Pfizer is trying to keep them in the auction, one of the people said. Bloomberg said a third bidder is no longer in the running.

Separately, Pfizer has hired JPMorgan Chase & Co, Bank of America Merrill Lynch and Morgan Stanley for a potential initial public offering of its animal health business, a source familiar with the situation said.

Pfizer put its infant nutrition and animal health businesses up for sale last July as it looks to focus on its core pharmaceuticals business.

A company official said on Tuesday that no decisions have been made and that Pfizer will be in a position to announce any decisions this year. The company expects to complete any transactions between July of this year and July 2013.

Regarding the animal health business, the official said a spin-off was most likely.

A Nestle spokesman was not immediately available for comment.

A person familiar with the negotiations said a deal for the infant nutrition unit was expected "in the near future," but not this week.

Pfizer's infant nutrition business sells baby formula and maternal supplements. It generates over 70 percent of its $2.1 billion in sales in emerging markets, with over a quarter coming from China, where the $6 billion market is expected to double by 2016.

The Pfizer business competes with products from Nestle and Danone, as well as Mead Johnson's Enfamil and Abbott Laboratories' Similac.

Pfizer shares closed 1.5 percent higher on Tuesday.

(Reporting by Olivia Oran, Ransdell Pierson, Martinne Geller and Michael Erman in New York; Editing by Gunna Dickson, Bernard Orr, Tim Dobbyn and Sugita Katyal)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Shares Hit Record

Sensex, Nifty rise to second consecutive record high

Sensex surges 500 points on BOJ easing, L&T gains

The BSE Sensex and Nifty surged to record highs for a second consecutive session on Friday after Bank of Japan's surprise expansion of its massive stimulus programme raised hopes for additional foreign inflows, boosting blue-chips such as Larsen & Toubro.  Full Article 

REUTERS SHOWCASE

Ban on E-Cigs?

Ban on E-Cigs?

Govt considers ban on e-cigarettes, sale of single smokes.  Full Article 

Commodities

Commodities

Silver futures in India hit four-year low on global cues.  Full Article 

BOJ Policy

BOJ Policy

BOJ shocks markets with surprise easing as inflation slows.  Full Article 

Cost Cutting

Cost Cutting

PM Narendra Modi boots officials out of the first class cabin  Full Article 

Leisure Riding

Leisure Riding

Harley-Davidson woos affluent young Indians with bike culture  Full Article 

Shadow Banking

Shadow Banking

China's shadow banking sector growing rapidly, third largest in world - FSB.  Full Article 

Moody's on India

Moody's on India

Moody's welcomes India's policy steps, but wants to see more.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage